Table 5.

FGF23 trajectories and risk of death

AnalysisTotal, NDeaths, NUnadjustedModel 1Model 2Model 3Model 4Model 5
Up to five annual time points, median duration of subsequent follow-up time 3.4 yr in 1309 total participants at risk
 Stable, lnFGF23 per 1 yr =0.03724102ReferenceReferenceReferenceReferenceReferenceReference
 Slowly rising, lnFGF23 per 1 yr =0.144862214.96 (3.83–6.43)5.27 (3.98–6.97)4.87 (3.55–6.68)4.86 (3.51–6.73)4.54 (3.20–6.44)4.49 (3.17–6.35)
 Rapidly rising, lnFGF23 per 1 yr =0.46996713.06 (8.50–20.07)18.16 (11.37–29.01)18.70 (11.22–31.16)17.98 (10.56–30.62)14.32 (7.73–26.55)15.23 (8.24–28.14)
Up to four annual time points, median duration of subsequent follow-up time 4.3 yr in 1376 total participants at risk
 Stable, lnFGF23 per 1 yr =0.06725113ReferenceReferenceReferenceReferenceReferenceReference
 Slowly rising, lnFGF23 per 1 yr =0.165282574.79 (3.75–6.10)5.03 (3.87–6.53)4.70 (3.50–6.31)4.19 (3.10–5.67)3.94 (2.84–5.47)4.06 (2.93–5.64)
 Rapidly rising, lnFGF23 per 1 yr =0.341238511.78 (8.00–17.35)14.59 (9.46–22.52)13.71 (8.63–21.79)13.66 (8.59–21.73)12.17 (7.10–20.87)12.63 (7.44–21.47)
Up to three annual time points, median duration of subsequent follow-up time 5.1 yr in 1412 total participants at risk
 Stable, lnFGF23 per 1 yr =0.05780137ReferenceReferenceReferenceReferenceReferenceReference
 Slowly rising, lnFGF23 per 1 yr =0.205282804.85 (3.86–6.08)5.15 (4.03–6.60)4.80 (3.64–6.33)4.08 (3.09–5.40)3.11 (2.30–4.22)3.28 (2.41–4.46)
 Rapidly rising, lnFGF23 per 1 yr =0.491047310.88 (7.21–16.43)13.28 (8.39–21.01)12.59 (7.66–20.70)12.04 (7.38–19.63)6.21 (3.56–10.85)6.54 (3.75–11.43)
  • Covariate adjustment is for covariates obtained at the analysis-specific time 0 except for baseline UACR and baseline eGFR, which are obtained at the CRIC Study baseline visit. Model 1: stratified by center and adjusted for age, sex, race, and ethnicity. Model 2: model 1 plus eGFR, baseline UACR, serum albumin, and hemoglobin. Model 3: model 2 plus diabetes, smoking, systolic BP, body mass index, history of coronary artery disease, history of heart failure, history of stroke, and history of peripheral vascular disease. Model 4: model 3 plus calcium, phosphate, PTH, lnFGF23, and baseline eGFR. Model 5: model 4 substituting eGFR trajectory groups for baseline and updated eGFR at time 0.